What is Abogen?
Founded in 2012, Abogen operates at the intersection of biotechnology and advanced diagnostics. The company is dedicated to the development of novel, non-invasive alternatives to blood-based sampling, aiming to revolutionize how clinicians and researchers obtain comprehensive genomic information. By focusing on high-precision diagnostic tools, Abogen addresses a critical gap in the personalized medicine market, enabling more tailored therapeutic interventions and improved patient outcomes. Its strategic focus on innovation has attracted a diverse syndicate of global investors, positioning the firm as a key player in the next generation of healthcare technology.
How much funding has Abogen raised?
Abogen has raised a total of $1.1B across 3 funding rounds:
Multiple Rounds
$1.1B
Series B (2021): $92M with participation from YF Capital, SDIC Venture Capital, Qiming Venture Partners, LYFE Capital, GL Ventures, HighLight Capital, PICC Capital Investment Management, Ming Bioventures, and TF Capital
Series C (2021): $700M led by Temasek and Invesco Developing Markets Fund
Unspecified (2021): $300M supported by 5Y Capital, Mirae Asset Financial, Fortune Ocean, SoftBank Group Corp, and Chimera Abu Dhabi
Key Investors in Abogen
Qiming Venture Partners
A prominent venture capital firm that focuses on investing in innovative companies across technology, healthcare, and artificial intelligence, providing industry resources and strategic guidance.
LYFE Capital
A premier healthcare investment platform that connects healthcare champions with global markets, focusing on critical supply chain assets and next-generation R&D services.
SoftBank Group Corp
A global technology holding company that drives innovation across AI, robotics, and clean energy, leveraging its Vision Fund to back businesses with the potential to shape the Information Revolution.
What's next for Abogen?
With the successful closure of its recent financing, Abogen is well-positioned to accelerate its R&D initiatives and scale its diagnostic platform for broader clinical adoption. The company's strategic roadmap involves deepening its footprint in global biopharma hubs and enhancing its proprietary technology stack to meet the increasing demand for high-fidelity genomic insights. As it transitions from a development-focused entity to a commercial-scale enterprise, Abogen will likely prioritize strategic partnerships and regulatory milestones to solidify its competitive advantage in the global healthcare market.
See full Abogen company page
